antileprosy

antileprosy

(ˌæntɪˈlɛprəsɪ)
adj
acting against leprosy
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
However, translation of existing knowledge has been poor and meagre, and if done seriously, would suffice to promote early detection and prompt effective antileprosy therapy and control of reactions.
In addition, all patients with resistance seemed to have primary resistance to dapsone because biopsies were taken before known treatment with antileprosy drugs.
After routine pretherapeutic laboratory examinations that proved to be normal, antileprosy treatment (rifampicin 600 mg/day, dapsone 100 mg/day, and clofazimine 100 mg/day) was prescribed and was generally well tolerated, resulting in good clinical progress.
Between the two antileprosy drugs included in this study, dapsone had better activity than clofazimine, even though clofazimine is a well-known second-line antileprosy drug [26].
Patients were either untreated or on antileprosy treatment for less than 3 months duration.
Important to mention here are dermatosis papulosa nigra, multiple genital warts due to unprotected sexual intercourse among homo- and heterosexual soldiers and few cases of leprosy who were eventually sent back to their native countries due to non-availability of antileprosy therapy.
Detection of Mycobacterium leprae and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR.
The old drug called clofazimine, made in the 1890s originally failed to treat tuberculosis but has worked well as an antileprosy medicine.
People with leprosy are treated with the antileprosy drug dapsone (DDS), which is bacteriostatic (often treatment lasts for life).
Inc., offering donations to treat river blindness, lymphatic filariasis, and MMR II; GlaxoSmithKline, donating doses of the meningitis vaccine, malarial treatment, and others; and Novartis, donating enough antileprosy multidrug therapy for all patients in the world until the end of 2005 together with funds for shipping and independent quality control.
leprae isolates studied show resistant mutations to either folP1/rpoB or gyrA, indicating that there is no primary resistance to antileprosy drugs in this part of India, which has a significantly higher leprosy incidence.
Because few alternative effective antileprosy drugs exist, resistance to these firstline drugs could seriously affect leprosy control programs.